| 000 | 01095 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250517193926.0 | ||
| 264 | 0 | _c20181102 | |
| 008 | 201811s 0 0 eng d | ||
| 022 | _a1365-2230 | ||
| 024 | 7 |
_a10.1111/ced.13384 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDolan, M | |
| 245 | 0 | 0 |
_aAssessment of a visual risk communication aid used to support patients with psoriasis in deciding about biological therapy. _h[electronic resource] |
| 260 |
_bClinical and experimental dermatology _c07 2018 |
||
| 300 |
_a594-596 p. _bdigital |
||
| 500 | _aPublication Type: Letter | ||
| 650 | 0 | 4 |
_aAudiovisual Aids _xstandards |
| 650 | 0 | 4 |
_aBiological Therapy _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aPatient Education as Topic _xmethods |
| 650 | 0 | 4 |
_aPsoriasis _xdrug therapy |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aConnolly, M | |
| 700 | 1 | _aTobin, A M | |
| 773 | 0 |
_tClinical and experimental dermatology _gvol. 43 _gno. 5 _gp. 594-596 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/ced.13384 _zAvailable from publisher's website |
| 999 |
_c27962340 _d27962340 |
||